Tag: REVOVAS

Revotek Receives Clearance from the National Health Commission of China for the World First Clinical Trial for 3D Bioprinted Stem Cell Vascular Grafts

CHENGDU, China, Feb. 21, 2022 /PRNewswire/ — Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS. “The clearance marks an important milestone for Revotek. We are excited to advance REVOVAS, our […]